Yuesong Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yuesong Wang has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
- Benjamin C. Blount
Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA 30341, USA
92 shared publications - Baoyun Xia
Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention , Atlanta, GA
90 shared publications - Cindy M. Chang
Center for Tobacco Products, Food and Drug Administration , Silver Spring, MD 20903
90 shared publications - Deepak Bhandari
Tobacco and Volatiles Branch, Division of Laboratory Sciences, National Center for Environmental Health
90 shared publications - Lanqing Wang
Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention , Atlanta, GA
90 shared publications - Heather L. Kimmel
National Institute on Drug Abuse, National Institutes of Health , Bethesda, MD
89 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Biomarkers of Opioids, Volatile Organic Compounds, and Polycyclic Aromatic Hydrocarbons and Lung Cancer Incidence among Opium Users
Supplementary Figure S1 shows Pearson correlation coefficients of opioid and nonopioid biomarkers related to opium use among those who use opium by smoking. Colors correspond to the color key on the right, showing the strength and direction of correlation. Squares marked with an “x” show statistically non-significant correlations.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Biomarkers of Opioids, Volatile Organic Compounds, and Polycyclic Aromatic Hydrocarbons and Lung Cancer Incidence among Opium Users
Supplementary Figure S1 shows Pearson correlation coefficients of opioid and nonopioid biomarkers related to opium use among those who use opium by smoking. Colors correspond to the color key on the right, showing the strength and direction of correlation. Squares marked with an “x” show statistically non-significant correlations.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Data from Biomarkers of Opioids, Volatile Organic Compounds, and Polycyclic Aromatic Hydrocarbons and Lung Cancer Incidence among Opium Users
Background:Opium consumption, a recognized carcinogen, is associated with lung cancer. However, the relative contributions of its potentially carcinogenic constituents to lung cancer risk remain unclear. Methods:We conducted a nested case–control study among opium users in the Golestan Cohort Study, including 53 incident lung cancer cases and 53 controls matched on age, sex, tobacco use, place of residence, and enrollment time. Urinary biomarkers of opioids, volatile organic compounds (VOC), polycyclic aromatic hydrocarbons (PAH), cotinine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), and creatinine were measured in baseline samples. Adjusted logistic regression analyses, as well as mediation analyses, were used to evaluate the associations between biomarker concentrations and lung cancer incidence. Results:We found statistically significant associations between 3- and 6-glucuronide of morphine, as well as metabolites of acrylonitrile/ethylene oxide (2-hydroxyethyl mercapturic acid) and propylene oxide (2-hydroxypropyl mercapturic acid), and lung cancer among opium users, especially those who smoked opium. Associations between VOC metabolites and lung cancer were independent of opioid biomarkers, and mediation analysis showed no evidence that VOCs mediate the effects of opioid biomarkers on lung cancer. No associations were observed for PAH biomarkers, cotinine and NNAL. Conclusions:Our findings provide biochemical evidence supporting the association between opium use and lung cancer, highlighting independent mechanisms related to both opioid and non-opioid components of opium, with varying effects by route of use. Impact:Opioids and chemical constituents produced during opium consumption must be considered in cancer risk assessment.See related In the Spotlight, p. 1801
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Biomarkers of Opioids, Volatile Organic Compounds, and Polycyclic Aromatic Hydrocarbons and Lung Cancer Incidence among Opium Users
Background:Opium consumption, a recognized carcinogen, is associated with lung cancer. However, the relative contributions of its potentially carcinogenic constituents to lung cancer risk remain unclear. Methods:We conducted a nested case–control study among opium users in the Golestan Cohort Study, including 53 incident lung cancer cases and 53 controls matched on age, sex, tobacco use, place of residence, and enrollment time. Urinary biomarkers of opioids, volatile organic compounds (VOC), polycyclic aromatic hydrocarbons (PAH), cotinine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), and creatinine were measured in baseline samples. Adjusted logistic regression analyses, as well as mediation analyses, were used to evaluate the associations between biomarker concentrations and lung cancer incidence. Results:We found statistically significant associations between 3- and 6-glucuronide of morphine, as well as metabolites of acrylonitrile/ethylene oxide (2-hydroxyethyl mercapturic acid) and propylene oxide (2-hydroxypropyl mercapturic acid), and lung cancer among opium users, especially those who smoked opium. Associations between VOC metabolites and lung cancer were independent of opioid biomarkers, and mediation analysis showed no evidence that VOCs mediate the effects of opioid biomarkers on lung cancer. No associations were observed for PAH biomarkers, cotinine and NNAL. Conclusions:Our findings provide biochemical evidence supporting the association between opium use and lung cancer, highlighting independent mechanisms related to both opioid and non-opioid components of opium, with varying effects by route of use. Impact:Opioids and chemical constituents produced during opium consumption must be considered in cancer risk assessment.See related In the Spotlight, p. 1801
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Biomarkers of Opioids, Volatile Organic Compounds, and Polycyclic Aromatic Hydrocarbons and Lung Cancer Incidence among Opium Users
Supplementary Figure S2 shows Pearson correlation coefficients of opioid and nonopioid biomarkers related to opium use among those who use opium by ingestion. Colors correspond to the color key on the right, showing the strength and direction of correlation. Squares marked with an “x” show statistically non-significant correlations.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Biomarkers of Opioids, Volatile Organic Compounds, and Polycyclic Aromatic Hydrocarbons and Lung Cancer Incidence among Opium Users
Supplementary Figure S2 shows Pearson correlation coefficients of opioid and nonopioid biomarkers related to opium use among those who use opium by ingestion. Colors correspond to the color key on the right, showing the strength and direction of correlation. Squares marked with an “x” show statistically non-significant correlations.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Biomarkers of Opioids, Volatile Organic Compounds, and Polycyclic Aromatic Hydrocarbons and Lung Cancer Incidence among Opium Users
Supplementary Figure S3 shows Pearson correlation coefficients of opioid and nonopioid biomarkers related to opium use in the total sample. Colors correspond to the color key on the right, showing the strength and direction of correlation. Squares marked with an “x” show statistically non-significant correlations.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Biomarkers of Opioids, Volatile Organic Compounds, and Polycyclic Aromatic Hydrocarbons and Lung Cancer Incidence among Opium Users
Supplementary Figure S3 shows Pearson correlation coefficients of opioid and nonopioid biomarkers related to opium use in the total sample. Colors correspond to the color key on the right, showing the strength and direction of correlation. Squares marked with an “x” show statistically non-significant correlations.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Biomarkers of Opioids, Volatile Organic Compounds, and Polycyclic Aromatic Hydrocarbons and Lung Cancer Incidence among Opium Users
Supplementary Table S2 shows Associations between VOC and PAH biomarkers and lung cancer, stratified by routes of opium use
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Biomarkers of Opioids, Volatile Organic Compounds, and Polycyclic Aromatic Hydrocarbons and Lung Cancer Incidence among Opium Users
Supplementary Table S2 shows Associations between VOC and PAH biomarkers and lung cancer, stratified by routes of opium use
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Biomarkers of Opioids, Volatile Organic Compounds, and Polycyclic Aromatic Hydrocarbons and Lung Cancer Incidence among Opium Users
Supplementary Table S3 shows Coefficients from mediation analysis on the indirect effect of VOC metabolites mediating the associations between morphine glucuronides and lung cancer (third tertile compared to first tertile) among people who used opium by smoking
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Biomarkers of Opioids, Volatile Organic Compounds, and Polycyclic Aromatic Hydrocarbons and Lung Cancer Incidence among Opium Users
Supplementary Table S3 shows Coefficients from mediation analysis on the indirect effect of VOC metabolites mediating the associations between morphine glucuronides and lung cancer (third tertile compared to first tertile) among people who used opium by smoking
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Biomarkers of Opioids, Volatile Organic Compounds, and Polycyclic Aromatic Hydrocarbons and Lung Cancer Incidence among Opium Users
Supplementary Table S1 shows Biomarkers related to opium exposure and their coefficients of variation
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Biomarkers of Opioids, Volatile Organic Compounds, and Polycyclic Aromatic Hydrocarbons and Lung Cancer Incidence among Opium Users
Supplementary Table S1 shows Biomarkers related to opium exposure and their coefficients of variation
- 18 May 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 35 (11) , 1880-1887
Biomarkers of Opioids, Volatile Organic Compounds, and Polycyclic Aromatic Hydrocarbons and Lung Cancer Incidence among Opium Users
Background: Opium consumption, a recognized carcinogen, is associated with lung cancer. However, the relative contributions of its potentially carcinogenic constituents to lung cancer risk remain unclear. Methods: We conducted a nested case–control study among opium users in the Golestan Cohort Study, including 53 incident lung cancer cases and 53 controls matched on age, sex, tobacco use, place of residence, and enrollment time. Urinary biomarkers of opioids, volatile organic compounds (VOC), polycyclic aromatic hydrocarbons (PAH), cotinine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), and creatinine were measured in baseline samples. Adjusted logistic regression analyses, as well as mediation analyses, were used to evaluate the associations between biomarker concentrations and lung cancer incidence. Results: We found statistically significant associations between 3- and 6-glucuronide of morphine, as well as metabolites of acrylonitrile/ethylene oxide (2-hydroxyethyl mercapturic acid) and propylene oxide (2-hydroxypropyl mercapturic acid), and lung cancer among opium users, especially those who smoked opium. Associations between VOC metabolites and lung cancer were independent of opioid biomarkers, and mediation analysis showed no evidence that VOCs mediate the effects of opioid biomarkers on lung cancer. No associations were observed for PAH biomarkers, cotinine and NNAL. Conclusions: Our findings provide biochemical evidence supporting the association between opium use and lung cancer, highlighting independent mechanisms related to both opioid and non-opioid components of opium, with varying effects by route of use. Impact: Opioids and chemical constituents produced during opium consumption must be considered in cancer risk assessment. See related In the Spotlight, p. 1801
- 18 May 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 35 (11) , 1880-1887
Biomarkers of Opioids, Volatile Organic Compounds, and Polycyclic Aromatic Hydrocarbons and Lung Cancer Incidence among Opium Users
Background: Opium consumption, a recognized carcinogen, is associated with lung cancer. However, the relative contributions of its potentially carcinogenic constituents to lung cancer risk remain unclear. Methods: We conducted a nested case–control study among opium users in the Golestan Cohort Study, including 53 incident lung cancer cases and 53 controls matched on age, sex, tobacco use, place of residence, and enrollment time. Urinary biomarkers of opioids, volatile organic compounds (VOC), polycyclic aromatic hydrocarbons (PAH), cotinine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), and creatinine were measured in baseline samples. Adjusted logistic regression analyses, as well as mediation analyses, were used to evaluate the associations between biomarker concentrations and lung cancer incidence. Results: We found statistically significant associations between 3- and 6-glucuronide of morphine, as well as metabolites of acrylonitrile/ethylene oxide (2-hydroxyethyl mercapturic acid) and propylene oxide (2-hydroxypropyl mercapturic acid), and lung cancer among opium users, especially those who smoked opium. Associations between VOC metabolites and lung cancer were independent of opioid biomarkers, and mediation analysis showed no evidence that VOCs mediate the effects of opioid biomarkers on lung cancer. No associations were observed for PAH biomarkers, cotinine and NNAL. Conclusions: Our findings provide biochemical evidence supporting the association between opium use and lung cancer, highlighting independent mechanisms related to both opioid and non-opioid components of opium, with varying effects by route of use. Impact: Opioids and chemical constituents produced during opium consumption must be considered in cancer risk assessment. See related In the Spotlight, p. 1801
- 18 March 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (8) , 1444-1452
Tobacco-related urinary biomarkers and lung cancer risk in women, a case-cohort analysis
Background: The constituents of tobacco smoke that specifically contribute to lung cancer risk have yet to be fully identified. We evaluated associations between biomarkers of potentially harmful constituents—polycyclic aromatic hydrocarbons, tobacco-specific nitrosamines, nicotine, and volatile organic compounds—and lung cancer incidence among US women. Methods: In a case-cohort study nested within the Sister Study (women aged 35-74 years at baseline, enrolled 2003-2009), data were obtained for a random subcohort and all remaining incident lung cancers through September 2017 (median follow-up = 9.6 years), stratified by race and ethnicity (Hispanic, non-Hispanic Black, non-Hispanic White, others) and smoking status (current, former, never). The analytic sample included 356 cases and 433 noncases. We quantified 30 biomarkers in baseline urine samples and calculated hazard ratios (HRs) for associations between 1-unit increase in biomarker concentrations (log-scale) and lung cancer incidence using weighted Cox regression models adjusted for urinary creatinine and demographic, health, and lifestyle factors. Results: Among women who were currently smoking at enrollment, positive associations were observed for biomarkers of polycyclic aromatic hydrocarbons (naphthalene, phenanthrene, pyrene, fluorene; HRs = 1.4-5.3), tobacco-specific nitrosamines (particularly 4-[methylnitrosamino]-1-[3-pyridyl]-1-butanone [nicotine-derived nitrosamine ketone]; HRs = 1.3-2.2), and volatile organic compounds (xylene, acrylamide, acrylonitrile, 1,2-dibromoethane and/or vinyl-chloride and/or ethylene-oxide and/or acrylonitrile, acrolein, styrene and/or ethylbenzene, benzene, dimethylformamide and/or methylisocyanate, 1,3-butadiene, crotonaldehyde, isoprene; HRs = 1.6-4.4). Associations with biomarkers of most polycyclic aromatic hydrocarbons, nicotine-derived nitrosamine ketone, xylene, and dimethylformamide and/or methylisocyanate remained after additional adjustment for smoking frequency, duration, and nicotine metabolites. In women who did not smoke, positive associations were observed for styrene and/or ethylbenzene and dimethylformamide and/or methylisocyanate biomarkers. Conclusion: Exposure to polycyclic aromatic hydrocarbons, tobacco-specific nitrosamines, and several volatile organic compounds through tobacco smoking were associated with increased lung cancer risk among women.
- 18 March 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (8) , 1444-1452
Tobacco-related urinary biomarkers and lung cancer risk in women, a case-cohort analysis
Background: The constituents of tobacco smoke that specifically contribute to lung cancer risk have yet to be fully identified. We evaluated associations between biomarkers of potentially harmful constituents—polycyclic aromatic hydrocarbons, tobacco-specific nitrosamines, nicotine, and volatile organic compounds—and lung cancer incidence among US women. Methods: In a case-cohort study nested within the Sister Study (women aged 35-74 years at baseline, enrolled 2003-2009), data were obtained for a random subcohort and all remaining incident lung cancers through September 2017 (median follow-up = 9.6 years), stratified by race and ethnicity (Hispanic, non-Hispanic Black, non-Hispanic White, others) and smoking status (current, former, never). The analytic sample included 356 cases and 433 noncases. We quantified 30 biomarkers in baseline urine samples and calculated hazard ratios (HRs) for associations between 1-unit increase in biomarker concentrations (log-scale) and lung cancer incidence using weighted Cox regression models adjusted for urinary creatinine and demographic, health, and lifestyle factors. Results: Among women who were currently smoking at enrollment, positive associations were observed for biomarkers of polycyclic aromatic hydrocarbons (naphthalene, phenanthrene, pyrene, fluorene; HRs = 1.4-5.3), tobacco-specific nitrosamines (particularly 4-[methylnitrosamino]-1-[3-pyridyl]-1-butanone [nicotine-derived nitrosamine ketone]; HRs = 1.3-2.2), and volatile organic compounds (xylene, acrylamide, acrylonitrile, 1,2-dibromoethane and/or vinyl-chloride and/or ethylene-oxide and/or acrylonitrile, acrolein, styrene and/or ethylbenzene, benzene, dimethylformamide and/or methylisocyanate, 1,3-butadiene, crotonaldehyde, isoprene; HRs = 1.6-4.4). Associations with biomarkers of most polycyclic aromatic hydrocarbons, nicotine-derived nitrosamine ketone, xylene, and dimethylformamide and/or methylisocyanate remained after additional adjustment for smoking frequency, duration, and nicotine metabolites. In women who did not smoke, positive associations were observed for styrene and/or ethylbenzene and dimethylformamide and/or methylisocyanate biomarkers. Conclusion: Exposure to polycyclic aromatic hydrocarbons, tobacco-specific nitrosamines, and several volatile organic compounds through tobacco smoking were associated with increased lung cancer risk among women.
- Open Access
- 9 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S30 from Influence of Half-life and Smoking/Nonsmoking Ratio on Biomarker Consistency between Waves 1 and 2 of the Population Assessment of Tobacco and Health Study
Supplementary Table S30 shows the results of weighted multiple linear regression analysis of log-transformed urinary phenylglyoxylic acid (PhGA) with study covariates
- 9 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S30 from Influence of Half-life and Smoking/Nonsmoking Ratio on Biomarker Consistency between Waves 1 and 2 of the Population Assessment of Tobacco and Health Study
Supplementary Table S30 shows the results of weighted multiple linear regression analysis of log-transformed urinary phenylglyoxylic acid (PhGA) with study covariates